HBIO · Harvard Bioscience, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on HBIO. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About HBIO · Harvard Bioscience, Inc.
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through websites and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic laboratories. It primarily sells its products under the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS, Warner, DSI, Panlab, Hugo Sachs, and Buxco brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
Live Quote
HOLD (score -1) · 12-1 mom 4.2% · RSI 49.4 · above_200_only · -23.9% from high
Targets blend Wall Street consensus (1 analysts: low $6.00 / mean $6.00 / high $6.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
Harvard Bioscience is a distressed micro-cap life sciences tools company (~$29M market cap) that executed a 10-for-1 reverse stock split on March 13, 2026. A genuine cluster of three directors and the CFO made open-market purchases in mid-March 2026 at $4.85-$5.00 — William Snider bought 21,000 shares, Stephen DeNelsky bought 10,000 shares, Mark Frost bought 5,000 shares. However, the fundamental picture is deeply troubled: accumulated deficit of $218M, stockholders' equity collapsed from $63M to $10M in one year after a $48M goodwill impairment, persistent operating losses, and high leverage (debt/equity 439%). The company has restructured its debt (Dec 2025 refinancing) and launched Project Viking consolidation expected to save ~$4M annually by 2028. The stock is near the top of its post-reverse-split range at $6.48 with no obvious near-term re-rating catalyst beyond Q2 earnings on Aug 10, 2026.